» Articles » PMID: 19302526

Identification of Multiple Sites Suitable for Insertion of Foreign Genes in Herpes Simplex Virus Genomes

Overview
Date 2009 Mar 24
PMID 19302526
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Information on sites in HSV genomes at which foreign gene(s) can be inserted without disrupting viral genes or affecting properties of the parental virus are important for basic research on HSV and development of HSV-based vectors for human therapy. The intergenic region between HSV-1 UL3 and UL4 genes has been reported to satisfy the requirements for such an insertion site. The UL3 and UL4 genes are oriented toward the intergenic region and, therefore, insertion of a foreign gene(s) into the region between the UL3 and UL4 polyadenylation signals should not disrupt any viral genes or transcriptional units. HSV-1 and HSV-2 each have more than 10 additional regions structurally similar to the intergenic region between UL3 and UL4. In the studies reported here, it has been demonstrated that insertion of a reporter gene expression cassette into several of the HSV-1 and HSV-2 intergenic regions has no effect on viral growth in cell culture or virulence in mice, suggesting that these multiple intergenic regions may be suitable HSV sites for insertion of foreign genes.

Citing Articles

Cas12f1 gene drives propagate efficiently in herpesviruses and induce minimal resistance.

Lin Z, Yao Q, Lai K, Jiao K, Zeng X, Lei G Genome Biol. 2024; 25(1):311.

PMID: 39696608 PMC: 11658101. DOI: 10.1186/s13059-024-03455-9.


Viral gene drive spread during herpes simplex virus 1 infection in mice.

Walter M, Haick A, Riley R, Massa P, Strongin D, Klouser L Nat Commun. 2024; 15(1):8161.

PMID: 39289368 PMC: 11408514. DOI: 10.1038/s41467-024-52395-2.


Identification of a novel neurovirulence factor encoded by the cryptic orphan gene UL31.6 of herpes simplex virus 1.

Kato A, Iwasaki R, Takeshima K, Maruzuru Y, Koyanagi N, Natsume T J Virol. 2024; 98(7):e0074724.

PMID: 38819171 PMC: 11265434. DOI: 10.1128/jvi.00747-24.


TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1.

Funk C, Uhlig N, Ruzsics Z, Baur F, Peindl M, Nietzer S Mol Ther Oncol. 2024; 32(1):200784.

PMID: 38596296 PMC: 10950833. DOI: 10.1016/j.omton.2024.200784.


A Recombinant System and Reporter Viruses for Papiine Alphaherpesvirus 2.

Siregar A, Gartner S, Gotting J, Stegen P, Kaul A, Schulz T Viruses. 2022; 14(1).

PMID: 35062295 PMC: 8778148. DOI: 10.3390/v14010091.